8-K: Village Farms Posts Record 2025 Profit, Expands Cannabis Ops

Village Farms International reported record full-year 2025 profitability with $21.0 million net income and $49.9 million Adjusted EBITDA from continuing operations, driven by strong cannabis segment growth and strategic expansions.

Summary

• Record Full Year 2025 Consolidated Net Income from Continuing Operations reached $21.0 million, or $0.19 per share, a significant improvement from a net loss of $27.9 million in 2024.
• Record Full Year 2025 Adjusted EBITDA from Continuing Operations was $49.9 million, up from $7.4 million in 2024.
• Record Full Year 2025 Operating Cash Flow from Continuing Operations increased to $58.1 million, compared to $13.7 million in 2024.
• Consolidated Q4 2025 Net Sales increased 9% year-over-year to $49.6 million.
• Canadian Cannabis sales increased 10% year-over-year in Q4 2025, with international export cannabis sales surging 384% year-over-year.
• Canadian Cannabis achieved a Q4 2025 Gross Margin of 43% and Adjusted EBITDA of $9.8 million (C$14.3 million).
• The Delta 2 expansion commenced cultivation on March 2, 2026, and is expected to harvest an incremental 15 tonnes of production capacity in 2026.
• The Netherlands expansion is on track to plant its first grow rooms in March 2026, with full facility completion during Q2 2026, anticipating approximately 10 tonnes of annual production capacity once fully ramped.
• The company ended 2025 with a strong cash position of $86 million.
• Village Farms completed $6.7 million of share repurchases since Q3 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, driven by record profitability, robust cash flow, and significant growth in international cannabis markets, despite some softness in U.S. cannabis and produce segments.

Positives

• Record full-year 2025 consolidated net income from continuing operations of $21.0 million ($0.19 per share), a significant improvement from a $27.9 million loss in 2024.
• Record full-year 2025 Adjusted EBITDA from continuing operations of $49.9 million, up from $7.4 million in 2024.
• Record full-year 2025 operating cash flow from continuing operations of $58.1 million, a substantial increase from $13.7 million in 2024.
• Q4 2025 consolidated net sales increased 9% year-over-year to $49.6 million.
• Canadian cannabis sales increased 10% year-over-year in Q4 2025 to $37.8 million (C$52.7 million).
• International export cannabis sales surged 384% year-over-year in Q4 2025, demonstrating strong global demand.
• Canadian cannabis gross margin improved significantly to 43% in Q4 2025 from 2% in Q4 2024, driven by operating efficiency and higher-margin sales.
• The Delta 2 expansion commenced cultivation on March 2, 2026, and is expected to harvest an incremental 15 tonnes of production capacity in 2026, remaining on time and under budget.
• The Netherlands Phase II facility is on track for first grow rooms to be planted in late Q1 2026, with full facility completion and planting by end of Q2 2026, expected to quintuple total annualized production to approximately 10 tonnes.
• The company ended 2025 with a strong cash position of $86 million.
• Repurchased $6.7 million of shares since Q3 2025, demonstrating commitment to shareholder value.
• Maintained a top five overall market share position in Canadian cannabis and held the number one position in dried flower as of February 2026.
• Netherlands products are now represented in 96% of participating coffeeshops, an increase of 500 basis points sequentially from Q3.
• Amended and extended Canadian cannabis credit facility by upsizing loan commitments with existing lenders by CAD $15 million and extending maturities one year, with variable interest rates currently below 6.0%.

Negatives

• U.S. Cannabis net sales decreased to $3.4 million in Q4 2025 from $4.6 million in Q4 2024.
• U.S. Cannabis gross margin decreased to 60% in Q4 2025 from 70% in Q4 2024.
• U.S. Cannabis segment reported a net loss of ($0.2 million) and Adjusted EBITDA of ($0.1 million) in Q4 2025.
• Produce sales from continuing operations were down to $4.9 million in Q4 2025 from $6.1 million in Q4 2024, due to commissions paid to Vanguard Food, L.P., and lower year-over-year pricing.
• Produce segment reported a net loss from continuing operations of ($1.6 million) and Adjusted EBITDA of ($462 thousand) in Q4 2025, compared to net income and positive EBITDA in the prior year which benefited from a legal settlement.
• Demand for products continues to significantly outpace current production capacity, leading to temporary supply constraints.
• Retail branded sales in Canadian cannabis were flat year-over-year in Q4 2025.

Risks

• Limited operating history in the cannabis and cannabinoids industry, including that of Pure Sunfarms, Rose LifeScience, Balanced Health, and Village Farms International B.V.
• Limited operational history of the Delta RNG Project in the energy segment and VF International.
• The legal status of the cannabis business and uncertainty regarding the legality and regulatory status of cannabis and cannabinoid (CBD) products in the United States.
• Risks relating to the implementation and enforcement of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension Act, 2026.
• Risks relating to the integration of Balanced Health and Rose into the consolidated business.
• Risks relating to obtaining additional financing on acceptable terms, including dependence upon credit facilities and dilutive transactions.
• Potential difficulties in achieving and/or maintaining profitability.
• Variability of product pricing.
• Risks inherent in the cannabis, hemp, CBD, cannabinoids, and agricultural businesses.
• The ability to leverage current business relationships for future business involving hemp and cannabinoids.
• The ability of Pure Sunfarms and Rose to cultivate and distribute cannabis in Canada as well as exports.
• Risks related to the start-up of international production at the Netherlands operations.
• Existing and new governmental regulations, including risks related to regulatory compliance and obtaining and maintaining licenses required under the Cannabis Act (Canada) and other Acts.
• Legal and operational risks relating to expected conversion of greenhouses to cannabis production in Canada and in the United States.
• Risks related to rules and regulations at the U.S. Federal (Food and Drug Administration and United States Department of Agriculture), state, and municipal levels with respect to produce and hemp, cannabidiol-based products commercialization.
• Retail consolidation, technological advances, and other forms of competition.
• Transportation disruptions.
• Product liability and other potential litigation.
• Retention of key executives.
• Labor issues.
• Uninsured and underinsured losses.
• Vulnerability to rising energy costs.
• Inflationary effects on costs of cultivation and transportation.
• Recessionary effects on demand of products.
• Environmental, health, and safety risks.
• Foreign exchange exposure, risks associated with cross-border trade, and the potential for tariffs and other trade restrictions.
• Difficulties in managing growth.
• Restrictive covenants under credit facilities.
• Natural catastrophes.
• Elevated interest rates.
• Tax risks.

Future Outlook

Village Farms expects to maintain a growth mindset for the remainder of 2026, balancing capital allocation with prudent consideration of accretive organic and acquisitive investments and ongoing share repurchases. The Delta 2 expansion is expected to harvest an incremental 15 tonnes of cannabis in 2026, and the Netherlands Phase II facility is anticipated to quintuple total annualized production to approximately 10 tonnes once fully ramped. The company also expects to return to sequential growth in international medical export sales in Q1 2026 and believes it is poised to benefit from potential U.S. marijuana rescheduling.

Management Comments

• "Our fourth quarter results again delivered strong profitability, gross margin and cash flow from operations which contributed to record levels of performance for each of these metrics in 2025." Michael DeGiglio, President and Chief Executive Officer.
• "Thanks to the tireless commitment and execution of our global team, this past year was a transformational one for Village Farms." Michael DeGiglio, President and Chief Executive Officer.
• "We are continuing to benefit from multiple catalysts unlocking value for our stakeholders and believe we remain in an excellent position to continue profitably scaling our platform in 2026." Michael DeGiglio, President and Chief Executive Officer.
• "Demand for our products continues to significantly outpace our current production capacity, and temporary supply constraints coupled with rapidly evolving global regulatory frameworks has created near-term variability in performance as we balance the complex needs of our diverse customer base." Michael DeGiglio, President and Chief Executive Officer.
• "We look to the remainder of 2026 with a growth mindset, and expect to maintain a balanced approach to capital allocation with prudent consideration of accretive organic and acquisitive investments and enhanced value creation for shareholders in the form of ongoing share repurchases." Michael DeGiglio, President and Chief Executive Officer.
• "We believe our growth investments, strong net cash position, industry leading cost of capital, and continued solid execution from our teams position us for continued success in 2026 and beyond." Michael DeGiglio, President and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Village Farms' strong performance in Canadian and international cannabis exports, coupled with strategic expansions in the Netherlands, positions it favorably within the evolving global cannabis market. The company's focus on EU-GMP certification and premium product categories aligns with increasing international demand for high-quality medical cannabis. The flat retail branded sales in Canada, however, suggest a maturing domestic market where differentiation and cost efficiency, as demonstrated by the improved gross margin, are crucial. The anticipation of U.S. marijuana rescheduling highlights a significant potential catalyst for the broader industry, which Village Farms is actively monitoring with its Texas license application.

Comparison to Industry Standards

• Village Farms' Canadian cannabis gross margin of 43% in Q4 2025 significantly surpasses the industry average for Canadian licensed producers, which often range from 20-30%, indicating superior operational efficiency and product mix.
• The 384% year-over-year increase in international export sales demonstrates exceptional growth compared to many Canadian peers who are still establishing their international footprints, positioning Village Farms as a leader in global medical cannabis supply, particularly to Europe.
• The company's claim of being the largest exporter of medical cannabis to Europe, with three of the top five leading cultivars in Germany, suggests a strong competitive advantage in a high-value market compared to other global cannabis producers.
• The Netherlands expansion, aiming for 10 tonnes of annual production capacity, places Village Farms among the larger licensed operators in the country's regulated cannabis program, a nascent but high-potential market.
• The flat retail branded sales in Canada, while offset by overall growth, indicate a competitive domestic market where companies like Canopy Growth or Tilray Brands face similar pressures, requiring strategic SKU management and innovation.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Sales from continuing operations in the Produce segment are net of a commission paid to Vanguard Food, L.P., in which Village Farms holds an equity interest.

Stakeholder Impact

• Shareholders: Positive impact due to record profitability, strong cash flow, share repurchases, and strategic growth initiatives aimed at long-term value creation.
• Employees: Positive impact through continued growth and expansion projects (Delta 2, Netherlands Phase II) which may lead to job creation and stability, as well as new leadership roles.
• Customers (Cannabis): Increased product availability and innovation, particularly in Canada and the Netherlands, with new packaging and product offerings.
• Customers (Produce): Potential impact from lower year-over-year pricing and commissions affecting sales, but the company continues to operate in this segment.
• Creditors: Positive impact from the extension and upsizing of the Canadian cannabis credit facility, indicating lender confidence and improved financial flexibility.

Next Steps

• Harvesting an incremental 15 tonnes of cannabis production capacity from the Delta 2 expansion during the remainder of 2026.
• Planting first grow rooms in the Netherlands Phase II facility in late Q1 2026.
• Full facility completion and planting of the Netherlands Phase II facility by the end of Q2 2026.
• Continuing to launch new and innovative products in the Netherlands market in 2026.
• Monitoring the review of the Texas medicinal marijuana license application by the Department of Public Services (DPS).
• Working with listing authority to structure an acceptable ownership structure if awarded a Texas license.
• Ongoing share repurchases under the US$10 million authorization.
• Maintaining a balanced approach to capital allocation with prudent consideration of accretive organic and acquisitive investments.
• Returning to sequential growth in international medical export sales in Q1 2026.

Key Dates

Recommendation

The company delivered record full-year profitability and cash flow, driven by strong performance in its Canadian and international cannabis segments. Strategic expansions in Delta 2 and the Netherlands are on track to significantly increase production capacity, addressing current demand outstripping supply. A robust cash position and ongoing share repurchases further enhance shareholder value. While U.S. cannabis and produce segments show some weakness, the overall growth trajectory, market leadership in key cannabis categories, and proactive capital management suggest strong future potential, making it an attractive investment.

Keywords

Village Farms International, VFF, Cannabis, Financial Results, Q4 2025, Full Year 2025, Adjusted EBITDA, Net Income, Greenhouse, Canada Cannabis, Netherlands Cannabis, US Cannabis, Share Repurchase, Delta 2 Expansion, EU-GMP, Medical Cannabis Export, Controlled Environment Agriculture